FOXP1 and urinary bladder cancer: Foxp1 has been found to bind to the upstream region of the β-adrenergic receptor (β-AR) promoter, inhibiting its expression, controlling brown/beige adipocyte differentiation, and promoting the progression of bladder cancer [50, 51].